Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Bayer HealthCare Pharmaceuticals Inc. announced today that new research studying BETASERON® (interferon beta-1b) will be presented at the 31st...
Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) approved BETACONNECT, the first and only electronic autoinjector in ...
Bayer HealthCare Pharmaceuticals Inc. announced today that data from its growing oncology portfolio will be presented at the 2015 European Cancer...
Bayer HealthCare today announced a new partnership with Coaches vs. Cancer, an awareness initiative led by the American Cancer Society and the...
Bayer HealthCare will host an event for members of the bleeding disorders community, patients and their families during the National Hemophilia...
Bayer HealthCare will present latest data from its investigational compound copanlisib at the 13th International Conference on Malignant Lymphoma...
While men living with advanced prostate cancer experience a range of symptoms like severe or unexplained pain, difficulty walking or climbing stairs, ...
Bayer is pleased to announce the winner of Breathless Moments, a photo contest designed to raise awareness about chronic thromboembolic pulmonary...
Bayer HealthCare Pharmaceuticals Inc. today announced the expansion of its patient assistance program for intrauterine devices (IUD). The ARCH...
Bayer HealthCare Pharmaceuticals Inc. announced today that new data on Xofigo® (radium Ra 223 dichloride) injection will be presented at the 2015...
Bayer HealthCare Pharmaceuticals Inc. announced today that data from its oncology portfolio, including Stivarga® (regorafenib) tablets, NEXAVAR®...
Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with...
Bayer HealthCare Inc. today announced that, approximately one year following the national launch, over 1,000 sites in the United States have received ...
Bayer HealthCare Pharmaceuticals Inc. today announced that the company has begun to enroll patients in a trial studying Xofigo® (radium Ra 223...
To raise awareness about colorectal cancer—the nation's second leading cause of cancer-related deaths—Fight Colorectal Cancer, a leading patient...
Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga® (regorafenib) tablets in...
Bayer HealthCare today announced positive results from the PROTECT VIII trial evaluating the company's investigational long-acting site-specific...
Bayer HealthCare and the National Hemophilia Foundation (NHF) today announced the successful conclusion of the third annual Virtual Walk for...
Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use (CHMP) recommended Xofigo® (radium Ra 223...
Bayer HealthCare today announced that data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial of its drug Xofigo®...
Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its investigational...
Intended for U.S. Media Only -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) approved Xofigo® (radium Ra 223...
Intended for U.S. Media Only -- Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets,...
Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular...
Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.